I think the 300 mg versus 700 mg with 30 patients in each arm and forgoing the dose escalation for a small group of patients for the first cycle, which is probably somewhere around two or three weeks saves us time and is an acknowledgment that the FDA knows LL needs to be on board. That’s why we are not being compared to standard of care but comparing just one dose of LL versus the other and we know 700 mg is going to blow the doors off of 350 mg So we can prove once and for all and I know people don’t like this because I don’t either that LL 700 mg will cover all receptors of expressed CCR five regardless whether there is minor expression in some patient or an over expression in some patients.

Then we go to the FDA and say OK there you go now we proved 700 mg is better than 350 mg and these are our survival rates and take a look at the safety by the way. Then maybe the next study includes ICIs In this most likely takes place after a deal. Hope big Pharma has deep pockets. And I don’t think it’s just the PD ones that are in dialogue. It’s other companies who don’t even have a PD one like JNJ and others with the pockets. May the highest bid win. And the antique just got much higher after yesterday’s press release.

Respert Posted something earlier commenting that maybe we land the biggest fish, but we have to figure out how to get it on the boat. I responded (deleted for whatever reason) we could tie it to The side of the boat like Santiago did in the old man and the sea, so the entire village could see the fish when we got back to shore after we fend off the sharks (shorts). We could call that story, the old J and the C